Implantable Cardioverter Defibrillator in Nonischemic Versus Ischemic Cardiomyopathy: Real‐World Primary Prevention Study
Pacing and Clinical Electrophysiology · 2025
DOI: 10.1111/pace.15142 ↗At a glance
Vergleichsstudie in Pacing and Clinical Electrophysiology, 2025. Written by Fankun Ma and 8 co-authors. Institution: Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China. Major MEDLINE topics: Defibrillators, Implantable, Cardiomyopathies, Death, Sudden, Cardiac, Primary Prevention. 23 references. Funded by: the National Key Research and Development Program of China.
Abstract (original language)
Background
The evidence in the primary prevention of sudden cardiac death (SCD) by using implantable cardioverter defibrillators (ICD) in patients with ischemic cardiomyopathy (ICM) is well‐established but remains controversial for those with nonischemic cardiomyopathy (NICM). This study evaluates whether prognostic differences exist between ICM and NICM patients after ICD implantation.
Methods
Patients initially undergoing ICD implantation as primary SCD prevention were retrospectively enrolled from January 2017 to May 2023. Malignant ventricular arrhythmic and/or SCD were set as the primary endpoint, whereas all‐cause mortality was the secondary endpoint. Patients were grouped by heart failure etiology (ICM vs. NICM) and then by primary endpoint events occurrence. Outcomes analyses were performed between the NICM and ICM patients.
Results
The final cohort had 342 patients, 213 (62.3%) with NICM and 129 (37.7%) with ICM. At a median follow‐up of 23.0 (10.7, 33.2) months, 51 patients (14.9%) encountered primary endpoint events. No statistically significant disparities in primary endpoint events (log rank p = 0.413), all‐cause death (log rank p = 0.208), cardiovascular mortality (log rank p = 0.218), or appropriate ICD therapy (log rank p = 0.250) between the two groups were indicated by Kaplan–Meier survival analysis. Moreover, the COX‐adjusted models further demonstrated the absence of any significant differences between the two groups.
Conclusion
In real‐world settings, primary prevention of SCD with ICD implantation yields similar outcomes for ICM and NICM patients, including probabilities of SCD and/or malignant ventricular arrhythmias, all‐cause mortality, appropriate ICD therapy, and cardiovascular mortality.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China.
ORCID profiles: Fankun Ma, Haibo Yu, Yanchun Liang
Funding
- the National Key Research and Development Program of China
Cite
APA
Ma, F., Gao, Y., Yu, H., Xu, G., Wu, M., Hao, X., Cui, Y., Peng, X., & Liang, Y. (2025). Implantable Cardioverter Defibrillator in Nonischemic Versus Ischemic Cardiomyopathy: Real‐World Primary Prevention Study. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.15142
Vancouver
Ma F, Gao Y, Yu H, Xu G, Wu M, Hao X, et al. Implantable Cardioverter Defibrillator in Nonischemic Versus Ischemic Cardiomyopathy: Real‐World Primary Prevention Study. Pacing and Clinical Electrophysiology. 2025. doi:10.1111/pace.15142
BibTeX
@article{Ma2025,
author = {Ma, Fankun and Gao, Yang and Yu, Haibo and Xu, Guoqing and Wu, Min and Hao, Xinrui and Cui, Yangfan and Peng, Xiao and Liang, Yanchun},
title = {Implantable Cardioverter Defibrillator in Nonischemic Versus Ischemic Cardiomyopathy: Real‐World Primary Prevention Study},
journal = {Pacing and Clinical Electrophysiology},
year = {2025},
doi = {10.1111/pace.15142}
}
EUVIMED